Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Background Twenty-five percent of T-ALL patients experience relapse after allo-HSCT, which indicates a dismal prognosis and represents a significant unmet clinical need. CD7 is continuously expressed on T-ALL cell surface at higher levels than that on normal T cells and is therefore considered as a viable CAR T therapeutic target. However, the impact of CD7-positive normal T and NK cell clearance…